Herzmann C, Lange C, Schaberg T, Ernst M, Ehlers S; for The TB or Not TB Consortium. Immunological Evidence of Incipient Pulmonary Tuberculosis. J Infect
Dis. 2012 Nov;206(10):1630-1631. Epub 2012 Sep 10

 

Günther G, Heyckendorf J, Herzmann C, Lange C. [Tuberculosis]. Dtsch Med Wochenschr. 2012 May;137(18):947-58; quiz 959-62. Epub 2012 Apr 26. Review.

 

Heyckendorf J, Kalsdorf B, Herzmann C, Günther G, Lange C, Tuberkulose – State of the Art. Kompendium Pneumologie 2012(1) 1, Georg Thieme Verlag KG

 

Günther G, Heyckendorf J, Herzmann C, Lange C. Tuberculosis. Dtsch Med Wochenschr. 2012 May;137(18):947-62. Epub 2012 Apr 26.

 

Herzmann C, Ernst M, Ehlers S, Stenger S, Maertzdorf J, Sotgiu G, Lange C. Increased frequencies of pulmonary Treg cells in latent M. tuberculosis infection. Eur Respir J. 2012 Mar 22.

 

Lange C, Herzmann C, Migliori GB, Gori A. Tuberculosis. p354-69 In: Hoffmann C, Rockstroh J. HIV Book 2011. Medizin Fokus Verlag, Hamburg. ISBN 978-3-941727-08-3

 

Herzmann C, Lange C, Stenger S, Maertzdorf J, Schaberg T, Sotgiu G, Ernst M. Latent tuberculosis infection is associated with an increased frequency of Treg cells in the bronchoalveolar lavage. Europ Respir Soc, Ann Congress 2011, Sep 24-28, Amsterdam, Poster 1809

 

Lange C, Herzmann C, Tuberkulose. P350-62. In: Hoffmann C, Rochstroh J. HIV Buch 2011. Medizin Fokus Verlag, Hamburg. ISBN-13: 978-3-941727-03-8

 

Herzmann C, Esser S, Lange C. Infections with non-tuberculous mycobacteria in HIV-infected patients. Hautarzt. 2011 Apr;62(4):272-9

 

Herzmann C, Smith C, Johnson MA, Byrne P, Terenghi G, et al. A Prospective, Double Blind, Randomised, Placebo Controlled Trial Evaluating Acetyl-L-Carnitine (ALCAR) for the Prevention of Distal Symmetric Polyneuropathy in HIV Infected Individuals. J AIDS Clinic Res 2010; 1:108. doi:10.4172/2155-6113.1000108

 

Herzmann C., Lange C. Infections with non-tuberculous mycobacteria and HIV. Dtsch Med Wochenschr. 2010 Jun;135(23):1192-7. Epub 2010 May 31.

 

Herzmann C., Arastéh K., Efavirenz induced osteomalacia. AIDS. 2009 Jan 14;23(2):274-5

 

Herzmann C., Jansen V. and Lichey J.. Bronchial cast formation associated with loss of immunoglobulin and calcium. Thorax, Aug 2008; 63: 754.

 

Herzmann C., Cuthbertson Z., Fosdick L., Fisher M., Nelson M., Perry N., Law M., Wand H., Janossy G., Johnson M.A., Youle M. Long-term clinical and surrogate marker effects of subcutaneous intermittent interleukin-2 without antiretroviral therapy in HIV-infected patients. J Antimicrob Chemother. 2008 Jun 27

 

Herzmann C., Whiting S.J., Thomas M., Byrne P., Johnson M.A., Youle M. Pharmacokinetics of Acetyl-L-Carnitine Given in Single or Multiple Doses to HIV-1 Infected Patients with Toxic Peripheral Polyneuropathy. The Open AIDS J 2008;2:39-42(4)

 

Stocker H., Herzmann C., Breske A., Kruse G., Berger M., Schulbin H., Hill A., Steinmüller J., Becker M., Arastéh K., Kurowski M., Saquinavir, Nelfinavir and M8 pharmacokinetics following Ritonavir and Nelfinavir administration. J Antimicrob Chemother. 2007 Mar;59(3):560-4

 

Youle M., Emery S., Fisher M., Nelson M., Fosdick L., Janossy G., Loveday C., Sullivan A., Herzmann C., et al., A randomised trial of subcutaneous intermittent interleukin-2 without antiretroviral therapy in HIV-infected patients: The UK-Vanguard study. PLoS Clin Trials 1(1): e3. DOI: 10. 1371/journal.pctr.0010003, 2006 May

 

Stocker H, Kloft C, Plock N, Breske A, Kruse G, Herzmann C, Schulbin H, Kreckel P, Weber C, Goebel F, Roeling J, Staszewski S, Plettenberg A, Moecklinghoff C, Arasteh K, Kurowski M. Pharmacokinetics of enfuvirtide in patients treated in typical routine clinical settings. Antimicrob Agents Chemother. 2006 Feb;50(2):667-73.

 

Herzmann C, Johnson MA, Youle M, Long-term effect of acetyl-L-carnitine for antiretroviral toxic neuropathy. HIV Clinical Trials 2005 Nov/Dec; 6(6): 344-350

 

Herzmann C, Kinloch S, Johnson MA (2005) Rash in an HIV-positive patient. HIV Medicine 2005 Nov; 6(6): 379

 

Herzmann C, Arastèh K, Murphy RL, Schulbin H, Kreckel P, Drauz D, Schinazi RF,  Beard A, Cartee L, Otto MJ. Safety, Pharmacokinetics and Efficacy of Racivir with Efavirenz and Stavudine in antiretroviral-naïve HIV-infected patients (AAC00901-04) Antimicrob Agents Chemother. 2005 Jul;49(7): 2828-33

 

Stocker, H., Kruse, G., Kreckel, P., Herzmann, C., Arasteh, K., Claus, J., Jessen, H., Cordes, C., Hintsche, B., Schlote, F., Schneider, L., Kurowski, M., (2004) Nevirapine significantly reduces the levels of racemic methadone and (R)-methadone in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2004 Nov;48(11):4148-53

 

Herzmann, C., Karcher, H., (2004) Nevirapine plus zidovudine to prevent mother-to-child transmission of HIV (Correspondence). N Engl J Med. 351(19):2013-5

 

Stocker, H., Kruse, G., Arastéh, A., Breske, A., Herzmann, C., Izbicki, D., Möcklinghoff, C., Hill, A., Kurowski, M., (2004) Pharmacokinetic interaction between Saquinavir/r and Nelfinavir in HIV-infected patients. (Poster 2058 at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, ICAAC, Washington DC)

 

Stocker, H., Kruse, G., Kreckel, P., Herzmann, C., Arastéh, K., Eskoetter, H., Claus, J., Jessen, H., Cordes, C., Hintsche, B., Schlote, F., Schneider, L., Kurowski, M. (2003) Nevirapine (NVP) significantly reduces methadone levels in HIV infected patients. (Poster for the  2nd International AIDS-Society Conference on HIV Pathogenesis and Treatment, Paris)

 

Herzmann, C., (2002) Interferon assay compared to tuberculin skin testing for latent tuberculosis detection. (Correspondence). JAMA. 2002 Jan 23-30; 287(4): 451-2.